摘要
目的:应用鼻-结膜炎相关生活质量问卷(RQLQ)评估药物或免疫治疗对成人变应性鼻炎(AR)患者生活质量的影响。方法:共纳入142例患者,其中接受特异性免疫治疗(SIT)的患者37例(SIT组);其余105例患者均接受规范化药物治疗,根据是否接受过药物应用的指导分为接受药物应用指导组(A1组)87例和未接受药物应用指导组(A2组)18例;根据是否接受过药物应用的监督分为接受药物应用监督组(B1组)33例和未接受药物应用监督组(B2组)72例。采用电话随访,应用RQLQ评估患者日常活动、睡眠、非鼻-眼症状、鼻部症状、眼部症状、实际问题及情感7大方向,共计28个小项的调查。研究数据用SPSS 17.0软件进行分析处理。结果:文化程度越高的AR患者生活质量评分越高(P<0.05)。AR患者性别对心理情感障碍的影响无统计学意义(P>0.05)。免疫治疗后对于鼻部症状、眼部症状的改善较治疗前明显(P<0.01)。SIT组和A1组治疗后鼻部症状的改善程度更为明显(P<0.05)。A1组和B1组治疗后生活质量均较治疗前明显改善(P<0.01)。接受治疗后A1组较A2组在生活质量上有明显改善(P<0.01或P<0.05);B1组较B2组在生活质量上有明显改善(P<0.05或P<0.01)。结论:AR患者无论接受单纯药物治疗还是免疫治疗,其生活质量均可得到一定程度的改善,SIT较药物治疗具有更好的疗效。加强用药指导和宣传教育可提高AR患者的生活质量。
Objective: Effects of drugs or immunotherapy on the quality of life of adult patients with allergic rhinitis(AR) were assessed using the rhinoconjunctivitis quality of life questionnaire(RQLQ). Method: A total of 142 patients were included, including 37 patients receiving specific immunotherapy(SIT)(SIT group). The remaining 105 patients received standardized drug treatment, and were divided into 87 cases in the receiving drug application instruction group(A1 group) and 18 cases in the non-receiving drug application instruction group(A2 group) according to whether or not receiving the drug application guidance group. According to whether or not receiving supervision of drug applications, they were divided into 33 cases of receiving drug application supervision group(B1 group) and 72 cases of non-receiving drug application supervision group(B2 group). Using telephone follow-up, RQLQ was used to evaluate the patients ’daily activities, sleep, non-nasal-eye symptoms, nasal symptoms, eye symptoms, practical problems, and emotional 7 major directions, a total of 28 small surveys. Research data was analyzed and processed by SPSS 17.0 software. Result: The higher the education level, the higher the quality of life score of patients with allergic rhinitis(P<0.05). There was no statistically significant effect of gender on psychomotor disorder in AR patients(P>0.05). Immunotherapy improved nasal and ocular symptoms and possess statistical significance(P<0.01). The improvement of nasal symptoms was more pronounced in SIT group and A1 group(P<0.05). The quality of life of A1 group and B1 group improved significantly after treatment(P<0.01). After treatment, A1 group had a significant improvement in quality of life compared to A2 group(P<0.01 or P<0.05);The B1 group had a significant improvement in the quality of life compared to the B2 group(P<0.05 or P<0.01). Conclusion: Life quality of AR patients can be improved to a certain extent, with simple drug therapy or immunotherapy, and SIT is more effective than drug therapy.
作者
刘奕麟
修倩
朱冬冬
孟粹达
LIU Yilin;XIU Qian;ZHU Dongdong;MENG Cuida(Department of Otolaryngology,China-Japan Union Hospital of Jilin University,Changchun,130031,China)
出处
《临床耳鼻咽喉头颈外科杂志》
CAS
北大核心
2020年第3期259-263,共5页
Journal of Clinical Otorhinolaryngology Head And Neck Surgery
关键词
鼻炎
变应性
特异性免疫治疗
生活质量
药物指导
用药监督
rhinitis,allergic
specific immunotherapy
quality of life
drugs therapy
drugs supervision
